Penser by Carnegie acted as sole global co-ordinator to Prostatype Genomics in a rights issue of approximately SEK 25 million.
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.